Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Inclusion Criteria:

Subjects with relapsed epithelial ovarian cancer (including fallopian tube and primary peritoneal cancer) who will receive liposomal doxorubicin as salvage therapy for recurrent disease
Patients may have received up to four previous lines of chemotherapy
The relapse may be defined by an increase in CA125; there may or may not be either measurable or symptomatic disease
Any human leukocyte antigen (HLA) type
No requirement for tumor expression of NY-ESO-1
Karnofsky performance status of > 70%
Not previously treated with doxorubicin
Life expectancy >= 6 months
Hematology and biochemistry laboratory results within the limits normally expected for the patient population, without evidence of major organ failure
No immunodeficiency
Have been informed of other treatment options
Able and willing to give valid written informed consent
Neutrophil count >= 1.5 x 10^9
Platelet count >= 100 x 10^9
Serum creatinine =< 2.1 mg/dL
Serum bilirubin =< 2 mg/dL
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.6 x upper limit of normal (ULN) (normal ranges: AST 15-46 U/L; ALT 11-66 U/L)

Exclusion Criteria:

Metastatic disease to the central nervous system for which other therapeutic options, including radiotherapy, may be available
Other serious illnesses (e.g., serious infections requiring antibiotics, bleeding disorders)
History of autoimmune disease (e.g., thyroiditis, lupus) except vitiligo
Concomitant systemic treatment with corticosteroids, anti-histamine or non-steroidal anti-inflammatory drugs; specific CQX-2 inhibitors are permitted
Chemotherapy, radiation therapy, or immunotherapy within 4 weeks prior to first dosing of study agent (6 weeks for nitrosoureas)
Known human immunodeficiency virus (HIV) positivity
Known allergy or history of life threatening reaction to GM-CSF
Myocardial infarction, angina, congestive heart failure, cardiomyopathy, stroke or transient ischemic attack, chest pain or shortness of breath with activity, or other heart conditions being treated by a doctor
Participation in any other clinical trial involving another investigational agent within 4 weeks prior to first dosing of study agent
Mental impairment that may compromise the ability to give informed consent and comply with the requirements of the study
Lack of availability of a patient for immunological and clinical follow-up assessment